Detalhe da pesquisa
1.
CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden.
Future Oncol
; 18(12): 1449-1459, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35040698
2.
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.
Lancet
; 394(10197): 478-487, 2019 08 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31229240
3.
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.
N Engl J Med
; 373(5): 428-37, 2015 Jul 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-26222558
4.
Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis.
N Engl J Med
; 368(4): 320-32, 2013 Jan 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-23343062
5.
Randomized Trial on the Effect of an Oral Spleen Tyrosine Kinase Inhibitor in the Treatment of IgA Nephropathy.
Kidney Int Rep
; 8(12): 2546-2556, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38106605
6.
Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
Clin Cancer Res
; 28(2): 298-307, 2022 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34716196